Ergomed plc John Dawson CBE Appointed to Ergomed Board as NED (1107E)
09 Marzo 2022 - 1:01AM
UK Regulatory
TIDMERGO
RNS Number : 1107E
Ergomed plc
09 March 2022
PRESS RELEASE
John Dawson CBE Appointed to the Board as Non-Executive
Director
Guildford, UK - 9 March 2022: Ergomed plc (LSE: ERGO) ("Ergomed"
or the "Company"), a company focused on providing specialised
services to the pharmaceutical industry, today announces that John
Dawson, CBE has joined the Board as an independent Non-Executive
Director and Chair of the Audit Committee.
John Dawson is a highly experienced and globally respected
figure in the healthcare sector. Most recently, he was Chief
Executive Officer of Oxford Biomedica (LSE: OXB) where, during his
13-year tenure, the business grew into a global market leader in
viral vector technologies for cell and gene therapy, delivered
multiple high value partnerships and successfully manufactured the
life-saving Oxford/AstraZeneca COVID-19 vaccine. Under Mr. Dawson's
leadership, Oxford Biomedica's success resulted in it entering the
FTSE 250 index in 2020. Subsequently, in the New Year Honours List
this year, he was awarded a CBE for services to UK life science, in
recognition of the unprecedented speed and success at which Oxford
Biomedica delivered the COVID-19 vaccine.
Prior to Oxford Biomedica, Mr. Dawson held various senior
executive roles including at Cephalon Pharmaceuticals where for
most of his tenure he was Managing Director for Europe. Prior to
this, he served as the Financial Director for Serono before its
acquisition by Merck. Mr. Dawson holds a BSc in Mathematics from
Swansea University and is a Chartered Accountant.
Dr. Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "As a highly regarded and well-connected figure, John is
an outstanding addition to the Ergomed Board, and his wealth of
international experience in the healthcare industry will be
invaluable as the Company continues to grow. The resounding success
of Oxford Biomedica is testament to John's strong leadership and
expert knowledge of the life science sector. We look forward to
utilising his network and benefiting from his extensive experience
of working in the UK public markets."
John Dawson, CBE, said: "Ergomed is fast becoming a leading
global pharmaceutical services provider, which has seen exceptional
growth over the past few years, and which remains at a very
exciting stage in its development. I look forward to working
closely with the Board and Senior Management Team as we continue to
build upon this momentum."
The following disclosures are made pursuant to AIM Rule 17 and
Schedule 2(g) of the AIM Rules for Companies:
Mr. John Andrew Dawson, aged 62, holds or has held directorships
in the five years preceding his appointment at Ergomed as
follows:
Current Directorships: Directorships in the past five
years:
Oxford Biomedica plc PAION AG
Oxford Biomedica (UK) Limited Ocquila Limited
OXB Solutions Limited
-------------------------------
There are no further disclosures to be made under Schedule 2(g)
of the AIM Rules for Companies.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President,
Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Tel: +44 (0) 20 7260
Broker) 1000
Freddie Barnfield / Euan Brown (Nominated
Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418
James Steel / Dr Christopher Golden 8900
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Matthew Neal/ Angela ergomed@consilium-comms.com
Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAJPMTTMTTMTBT
(END) Dow Jones Newswires
March 09, 2022 02:01 ET (07:01 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024